Case Report: Partial response to single-agent pembrolizumab in a chemotherapy-resistant metastatic pancreatic cancer patient with a high tumor mutation burden

被引：0
作者：
Dai, Mengyao [1 ,2 ,3 ,4 ]
Sheng, Jianpeng [1 ,2 ,3 ]
Zhang, Qi [1 ,2 ,3 ,5 ]
Wang, Jianxin [1 ,2 ,3 ,5 ]
Fu, Qihan [1 ,2 ,3 ,4 ]
Liang, Tingbo [1 ,2 ,3 ,5 ]
机构：
[1] Key Lab Pancreat Dis Zhejiang Prov, Hangzhou, Peoples R China
[2] Innovat Ctr Study Pancreat Dis Zhejiang Prov, Hangzhou, Peoples R China
[3] Zhejiang Clin Res Ctr Hepatobiliary & Pancreat Dis, Hangzhou, Peoples R China
[4] Zhejiang Univ, Affiliated Hosp 1, Dept Med Oncol, Sch Med, Hangzhou, Peoples R China
[5] Zhejiang Univ, Affiliated Hosp 1, Dept Hepatobiliary & Pancreat Surg, Sch Med, Hangzhou, Peoples R China
来源：
FRONTIERS IN ONCOLOGY | 2023年 / 13卷
基金：
中国国家自然科学基金;
关键词：
molecular alterations; pancreatic cancer; immunotherapy; tumor mutation burden (TMB); cyTOF; CELL-BASED IMMUNOTHERAPY; POTENTIAL BIOMARKER; BREAST-CANCER; EXPRESSION; SURVIVAL; MIRNA;
D O I：
10.3389/fonc.2023.1118633
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Single-agent immune checkpoint blockade has shown no clinical benefits in pancreatic cancer. Recently, the programmed cell death protein 1 (PD-1) antibody pembrolizumab has been recommended as a treatment option for high tumor mutational burden (TMB) solid tumors based on the data from a basket trial. However, no pancreatic cancer patients were enrolled in that trial. Whether pancreatic cancer patients with high TMB respond to PD-1 blockade as well remains unclear. Here, we report a case with a partial response to single-agent immunotherapy with pembrolizumab in pancreatic cancer with high TMB after the failure of several lines of chemotherapy. This result indicates that single-agent immunotherapy may be effective in pancreatic cancer patients with high TMB. In addition, in order to understand the basic immune state of our patients, we also analyzed the changes in immune cells in peripheral blood with cytometry by time-of-flight mass spectrometry (CyTOF) before and after pembrolizumab treatment.
引用
收藏
页数：6
相关论文
共 36 条
[1]   Combined Antiangiogenic Therapy and Immunotherapy Is Effective for Pancreatic Cancer With Mismatch Repair Proficiency but High Tumor Mutation Burden A Case Report [J].
Chen, Mengni ;
Yang, Shengli ;
Fan, Li ;
Wu, Lu ;
Chen, Renwang ;
Chang, Jian ;
Hu, Jianli .
PANCREAS, 2019, 48 (09) :1232-1236
[2]   FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer [J].
Conroy, Thierry ;
Desseigne, Francoise ;
Ychou, Marc ;
Bouche, Olivier ;
Guimbaud, Rosine ;
Becouarn, Yves ;
Adenis, Antoine ;
Raoul, Jean-Luc ;
Gourgou-Bourgade, Sophie ;
de la Fouchardiere, Christelle ;
Bennouna, Jaafar ;
Bachet, Jean-Baptiste ;
Khemissa-Akouz, Faiza ;
Pere-Verge, Denis ;
Delbaldo, Catherine ;
Assenat, Eric ;
Chauffert, Bruno ;
Michel, Pierre ;
Montoto-Grillot, Christine ;
Ducreux, Michel .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (19) :1817-1825
[3]   Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver [J].
Costa-Silva, Bruno ;
Aiello, Nicole M. ;
Ocean, Allyson J. ;
Singh, Swarnima ;
Zhang, Haiying ;
Thakur, Basant Kumar ;
Becker, Annette ;
Hoshino, Ayuko ;
Mark, Milica Tesic ;
Molina, Henrik ;
Xiang, Jenny ;
Zhang, Tuo ;
Theilen, Till-Martin ;
Garcia-Santos, Guillermo ;
Williams, Caitlin ;
Ararso, Yonathan ;
Huang, Yujie ;
Rodrigues, Goncalo ;
Shen, Tang-Long ;
Labori, Knut Jorgen ;
Lothe, Inger Marie Bowitz ;
Kure, Elm H. ;
Hernandez, Jonathan ;
Doussot, Alexandre ;
Ebbesen, Saya H. ;
Grandgenett, Paul M. ;
Hollingsworth, Michael A. ;
Jain, Maneesh ;
Mallya, Kavita ;
Batra, Surinder K. ;
Jarnagin, William R. ;
Schwartz, Robert E. ;
Matei, Irina ;
Peinado, Hector ;
Stanger, Ben Z. ;
Bromberg, Jacqueline ;
Lyden, David .
NATURE CELL BIOLOGY, 2015, 17 (06) :816-+
[4]   Specific targeting of CD163+ TAMs mobilizes inflammatory monocytes and promotes T cell-mediated tumor regression [J].
Etzerodt, Anders ;
TsaLkitzi, Kyriaki ;
Maniecki, Maciej ;
Damsky, William ;
Delfini, Marcello ;
Baudoin, ELodie ;
Moulin, Morgane ;
Bosenberg, Marcus ;
Graversen, Jonas Heilskov ;
Auphan-Anezin, Nathalie ;
Moestrup, Soren Kragh ;
Lawrence, Toby .
JOURNAL OF EXPERIMENTAL MEDICINE, 2019, 216 (10) :2394-2411
[5]   CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma [J].
Fukunaga, A ;
Miyamoto, M ;
Cho, Y ;
Murakami, S ;
Kawarada, Y ;
Oshikiri, T ;
Kato, K ;
Kurokawa, T ;
Suzuoki, M ;
Nakakubo, Y ;
Hiraoka, K ;
Itoh, T ;
Morikawa, T ;
Okushiba, S ;
Kondo, S ;
Katoh, H .
PANCREAS, 2004, 28 (01) :E26-E31
[6]   Molecular landscape of pancreatic cancer: implications for current clinical trials [J].
Heestand, Gregory M. ;
Kurzrock, Razelle .
ONCOTARGET, 2015, 6 (07) :4553-4561
[7]  
Hou XM, 2021, AM J TRANSL RES, V13, P8589
[8]   Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study [J].
Hui, Rina ;
Ozguroglu, Mustafa ;
Villegas, Augusto ;
Daniel, Davey ;
Vicente, David ;
Murakami, Shuji ;
Yokoi, Takashi ;
Chiappori, Alberto ;
Lee, Ki Hyeong ;
de Wit, Maike ;
Cho, Byoung Chul ;
Gray, Jhanelle E. ;
Ryden, Anna ;
Viviers, Louis ;
Poole, Lynne ;
Zhang, Yiduo ;
Dennis, Phillip A. ;
Antonia, Scott J. .
LANCET ONCOLOGY, 2019, 20 (12) :1670-1680
[9]   Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options [J].
Kabacaoglu, Derya ;
Ciecielski, Katrin J. ;
Ruess, Dietrich A. ;
Alguel, Hana .
FRONTIERS IN IMMUNOLOGY, 2018, 9
[10]   CD4+ T-cell Immunity in the Peripheral Blood Correlates with Response to Anti-PD-1 Therapy [J].
Kagamu, Hiroshi ;
Kitano, Shigehisa ;
Yamaguchi, Ou ;
Yoshimura, Kenichi ;
Horimoto, Katsuhisa ;
Kitazawa, Masashi ;
Fukui, Kazuhiko ;
Shiono, Ayako ;
Mouri, Atsuhito ;
Nishihara, Fuyumi ;
Miura, Yu ;
Hashimoto, Kosuke ;
Murayama, Yoshitake ;
Kaira, Kyoichi ;
Kobayashi, Kunihiko .
CANCER IMMUNOLOGY RESEARCH, 2020, 8 (03) :334-344
1234